Cargando…

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma

Detalles Bibliográficos
Autores principales: Sivaraj, Dharshan, Green, Michael M, Kang, Yubin, Long, Gwynn D, Rizzieri, David A, Li, Zhiguo, Garrett, Anderson H, McIntyre, Jackie L, Chao, Nelson J, Gasparetto, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068091/
https://www.ncbi.nlm.nih.gov/pubmed/30065277
http://dx.doi.org/10.1038/s41408-018-0104-5
_version_ 1783343206819168256
author Sivaraj, Dharshan
Green, Michael M
Kang, Yubin
Long, Gwynn D
Rizzieri, David A
Li, Zhiguo
Garrett, Anderson H
McIntyre, Jackie L
Chao, Nelson J
Gasparetto, Cristina
author_facet Sivaraj, Dharshan
Green, Michael M
Kang, Yubin
Long, Gwynn D
Rizzieri, David A
Li, Zhiguo
Garrett, Anderson H
McIntyre, Jackie L
Chao, Nelson J
Gasparetto, Cristina
author_sort Sivaraj, Dharshan
collection PubMed
description
format Online
Article
Text
id pubmed-6068091
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-60680912018-08-01 Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma Sivaraj, Dharshan Green, Michael M Kang, Yubin Long, Gwynn D Rizzieri, David A Li, Zhiguo Garrett, Anderson H McIntyre, Jackie L Chao, Nelson J Gasparetto, Cristina Blood Cancer J Correspondence Nature Publishing Group UK 2018-07-31 /pmc/articles/PMC6068091/ /pubmed/30065277 http://dx.doi.org/10.1038/s41408-018-0104-5 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Correspondence
Sivaraj, Dharshan
Green, Michael M
Kang, Yubin
Long, Gwynn D
Rizzieri, David A
Li, Zhiguo
Garrett, Anderson H
McIntyre, Jackie L
Chao, Nelson J
Gasparetto, Cristina
Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
title Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
title_full Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
title_fullStr Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
title_full_unstemmed Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
title_short Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
title_sort bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068091/
https://www.ncbi.nlm.nih.gov/pubmed/30065277
http://dx.doi.org/10.1038/s41408-018-0104-5
work_keys_str_mv AT sivarajdharshan bendamustinepomalidomideanddexamethasoneforrelapsedandorrefractorymultiplemyeloma
AT greenmichaelm bendamustinepomalidomideanddexamethasoneforrelapsedandorrefractorymultiplemyeloma
AT kangyubin bendamustinepomalidomideanddexamethasoneforrelapsedandorrefractorymultiplemyeloma
AT longgwynnd bendamustinepomalidomideanddexamethasoneforrelapsedandorrefractorymultiplemyeloma
AT rizzieridavida bendamustinepomalidomideanddexamethasoneforrelapsedandorrefractorymultiplemyeloma
AT lizhiguo bendamustinepomalidomideanddexamethasoneforrelapsedandorrefractorymultiplemyeloma
AT garrettandersonh bendamustinepomalidomideanddexamethasoneforrelapsedandorrefractorymultiplemyeloma
AT mcintyrejackiel bendamustinepomalidomideanddexamethasoneforrelapsedandorrefractorymultiplemyeloma
AT chaonelsonj bendamustinepomalidomideanddexamethasoneforrelapsedandorrefractorymultiplemyeloma
AT gasparettocristina bendamustinepomalidomideanddexamethasoneforrelapsedandorrefractorymultiplemyeloma